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OBJECTIVES The goal of this study was to investigate the dose-dependent effects of active cigarette
smoking on endothelial nitric oxide (NO) and endothelin-1 (ET-1) biosynthesis.
BACKGROUND Limited studies have suggested that active cigarette smoking may be associated with a
dose-dependent reduction of endothelium-dependent vasodilation (EDV). The underlying
biochemical changes that cause this dose-specific effect, such as changes in the endothelial
NO biosynthetic pathway and ET-1 production, have not been examined.
METHODS Flow- and nitroglycerin-mediated reactivity of the brachial artery were measured in eight
nonsmokers, seven light smokers (1 pack/week) and eight heavy smokers (1 pack/day),
and their sera were added to confluent (85%) monolayers of human umbilical endothelial
cells (HUVECs) for 12 h. Basal and substance P-stimulated NO and basal ET-1
production were measured. The HUVECs used for measuring basal NO production were
lysed, and both endothelial NO synthase (eNOS) protein expression and eNOS activity
were determined.
RESULTS Serum cotinine level and pack-years of smoking were significantly lower in light smokers
compared with heavy smokers (p  0.006 and p  0.004, respectively). There were no
significant differences between heavy smokers and light smokers in EDV (p  0.52), basal-
(p  0.70) and stimulated-NO production (p  0.95), eNOS protein (p  0.40) and eNOS
activity (p  0.63). Compared with nonsmokers, all the parameters were significantly altered
in both of the smokers’ groups. No differences were found in nitroglycerin-mediated
vasodilation and in vitro ET-1 production among the three groups.
CONCLUSIONS These results indicate light smoking may have similar detrimental effects on EDV and NO
biosynthetic pathway as does heavy smoking. These data may have important implications
concerning the amount of active cigarette exposure that imparts cardiovascular risk. (J Am
Coll Cardiol 2002;39:1758–63) © 2002 by the American College of Cardiology Foundation
Cigarette smoking is a recognized risk factor for cardiovas-
cular disease and is known to promote the development of
atherosclerosis and thrombosis (1,2). Endothelial dysfunc-
tion and early artherogenesis, increased procoagulation and
platelet activity as well as hypertension and vasospasm have
all been documented either clinically or in various experi-
mental models (1–3). While this association between smok-
ing and cardiovascular risk has clearly been demonstrated,
an unanswered question related to smoking is whether or
not there is a linear dose effect in active smokers. Early
epidemiologic studies suggested a direct dose effect with a
greater risk for heavy smokers in comparison with lighter
smokers (4). However, several recent large epidemiologic
studies, although showing a trend for more cardiovascular
events in heavier smokers, have failed to find a significant
dose-dependent correlation between the risk of cardiovas-
cular disease and the number of cigarettes smoked or the
pack-years of smoke exposure (5,6). Furthermore, smoking
as few as one to four cigarettes per day was associated with
a doubling of risk for coronary artery disease in the Nurses’
Health Study (7).
It has been shown that cigarette smoking is associated
with a reduction of endothelium-dependent vasodilation
(EDV) (8 –16). However, data regarding the dose-
dependent effects of smoking on EDV are limited and
inconclusive (8,13–15). Celermajer et al. (8,13) suggested
that both active and passive smoking were associated with a
dose-dependent decrease in EDV, but in other studies this
dose-dependent effect was not evident (14,15). We have
previously described a physiologic in vitro model to study
the effects of smoking on the NO biosynthetic pathway and
validated this model with in vivo measurements of EDV of
the brachial artery (16). In the present study, the effects of
light and heavy cigarette smoking exposure on endothelial
cell (EC)-derived vasoregulatory factors (nitric oxide [NO],
endothelin-1 [ET-1]) as well as EDV of the brachial artery
were assessed to determine whether or not there is a
dose-dependent effect of active smoking on endothelial
vasoregulatory function.
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METHODS
Subjects and study design. Male volunteers with a history
of active smoking were matched for age and gender with
individuals who had never smoked. Active smokers were
subclassified into two groups: light smokers (with smoking
habit of 1 pack/week) and heavy smokers (with smoking
habit of 1 pack/day). All subjects were free of other
cardiovascular risk factors (i.e., hypertension, diabetes, low
high-density lipoprotein, hyperlipidemia or a family history
of premature vascular disease) and were not taking any
medication.
Subjects were requested to abstain from smoking and
foods or caffeinated drinks for 6 to 8 h (overnight). On
arrival in the morning, subjects were allowed to rest for
20 min. Baseline blood pressure and heart rate were re-
corded, and blood was collected from the anticubital vein.
This was followed by an in vivo assessment of endothelial
function by utilizing ultrasonography to measure the bra-
chial artery diameter at rest, during reactive hyperemia
(leading to flow-mediated endothelium-dependent dilation)
and after administration of 400 g of sublingual nitroglyc-
erin (an endothelium-independent dilator) as previously
described (8,16). All ultrasonographic scans were obtained
utilizing the same equipment (Acuson L10 6-11 MHz
transducer and Acuson Aspen System, Mountain View,
California).
Blood for in vitro and biochemical studies (lipid profile
and serum cotinine) was collected in vacutainer tubes and
centrifuged at 1,776 g (3,000 rpm) for 15 min (4°C). The
serum was collected and stored at70°C until use. Analysis
for the lipid profile was done in the hospital’s clinical
laboratory, and serum cotinine concentrations were deter-
mined by a commercially available ELISA kit (STC Tech-
nologies, Bethlehem, Pennsylvania).
The study protocol was approved by Saint Vincent
Catholic Medical Centers of New York Ethics Committee,
and written informed consent was obtained from each
subject.
Determination of EDV and endothelium-independent
vasodilation. All brachial artery scans were read by a
single, experienced, ultrasonographer (J. G. Z.) who was
blinded to the identity of the participants and stage of the
experiment. The validated method of analysis has been
published previously (8,16). In brief, a pneumatic cuff
was inflated around the right forearm to 300 mm Hg for
4.5 min followed by cuff deflation. Flow-mediated EDV
was calculated by dividing the maximum vessel diameter at
50 to 60 s after cuff deflation with average baseline diameter.
Endothelium-independent dilation was calculated as the
maximum vessel diameter at 3 to 4 min after nitroglycerin
administration divided by average baseline diameter. The
arterial diameter was measured using ultrasonic calipers for
four cardiac cycles for each condition and was averaged.
Diameter measurements were taken at end diastole, coinci-
dent with the R wave on a continuously recorded electro-
cardiographic trace. Results were expressed as percentage
changes from the baseline.
EC culture and treatment. Primary human umbilical en-
dothelial cells (HUVEC) from a single donor were pur-
chased from Clonetics (BioWhittaker, Walkersville, Mary-
land). Human umbilical endothelial cells were cultured
using the method described previously (16). In brief, 20,000
cells/well were plated in 24-well, flat bottom, tissue culture
plates (Primaria, Baxter Scientific Products, Springfield,
New Jersey) with complete endothelial growth media
(EGM) (Clonetics) and grown to85% confluence at 37°C
in 5% CO2. The supernatant was removed from confluent
cells and incubated with an equal volume of serum and
EGM for 12 h (37°C; 5% CO2). All in vitro experiments
were carried out, during the second passage of the
HUVECs, by the same investigator (R. S. B.) who was
blinded to the identity of the participant and the clinical
data.
Determination of NO production, endothelial NO syn-
thase (eNOS) expression and eNOS activity. As de-
scribed above, HUVECs were treated for 12 h with equal
volumes of serum and EGM (total volume: 400 l) in
24-well tissue culture plates. After 12 h, basal NO produc-
tion in the supernatant was determined. To measure stim-
ulated NO production in culture, the supernatants were
removed after 12 h and the cells washed twice with
Dulbecco’s phosphate buffered saline (Gibco BRL, Grands
Island, New York). Fresh EGM was added to each well
followed by stimulation with 106 M substance P (SP)
(Sigma, St. Louis, Missouri) for 30 min. Cell culture
supernatants were collected and stored at 70°C until
analyzed. Nitric oxide concentration in each sample was
determined by the chemiluminesence method as described
previously using a NO analyzer (Sievers, Model # 280,
Boulder, Colorado) and expressed as nM after adjusting for
background NO levels (16).
The eNOS protein concentration of the HUVECs in
culture was determined using a commercial ELISA kit
(R&D Systems, Minneapolis, Minnesota) and expressed as
pg/ml as published previously (16).
The cell lysates generated for the eNOS protein assay
were also used to determine the specific eNOS activity. This
was done using a method described previously (16). Both
Abbreviations and Acronyms
ANOVA  analysis of variance
EC  endothelial cells
EDV  endothelium-dependent vasodilation
EGM  endothelial growth media
eNOS  endothelial nitric oxide synthase
ET-1  endothelin-1
HUVEC  human umbilical endothelial cells
mRNA  messenger ribonucleic acid
NO  nitric oxide
PLSD  protected least significant difference
SP  substance P
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eNOS concentration and eNOS activity assays were run
simultaneously. The eNOS activity in each sample was
adjusted to the specific amount of eNOS protein detected
by ELISA, and the specific activity of eNOS was expressed
as pmol L-citrulline/min/pg of eNOS protein.
Determination of ET-1 production. Nitric oxide and
ET-1 were detected from the same cell-culture supernatant.
Endothelin-1 concentrations were determined by using a
commercial ELISA kit (Amersham, Arlington Heights,
Illinois) and expressed as pg/ml after adjusting for back-
ground levels.
Statistical and power analyses. Results are presented as
the mean  SEM and all in vitro data are the average of
duplicate measurements. One-way analysis of variance
(ANOVA) was performed to compare values between
nonsmokers, light smokers and heavy smokers. For each
ANOVA, post-hoc Fisher PLSD (protected least signifi-
cant difference) was performed to determine each individual
group difference. The relationships between the degree of
smoke exposure (as measured by the pack-year and serum
cotinine levels) and EDV or NO were determined using
linear regression analysis. A value of p  0.05 was consid-
ered statistically significant.
As new in vitro methods have been described in this
study, an accurate assumption for the difference between
light and heavy smokers in vitro was difficult. For in vivo
data, Celermajer et al. (8) have reported a mean absolute
difference of 4% in EDV between very light (6.6%) and
heavy (2.6%) smokers with a pooled SD of 2.9%. Although,
the grouping criteria for smokers in their study were
different from ours (pack-years of smoking as opposed to
numbers of cigarette smoked), the pack-years of smoking in
the corresponding groups were comparable between the two
studies. Using their finding with the assumption that light
smokers will have higher EDV compared with heavy
smokers (i.e., one-sided), a sample size of seven to eight in
each group had an 80% power at   0.05. Power analyses
were performed using the STPLAN statistical software
(version 4.1, University of Texas M.D. Anderson Cancer
Center, Dept. of Biomathematics, Houston, Texas), and all
the other analyses were performed using the StatView
statistical program (version 4.5, Abacus Concepts, California).
RESULTS
Clinical characteristics of the study population. There
was no significant difference in age, systolic or diastolic
blood pressure, heart rate, total cholesterol, low-density
lipoprotein, high-density lipoprotein and triglyceride levels
between nonsmokers, light smokers and heavy smokers.
Serum cotinine levels, number of cigarette smoked per day
and pack-years of smoking were significantly different be-
tween all the groups substantiating the smoking status of the
study population (Table 1).
Brachial artery reactivity to flow and nitroglycerin. Base-
line brachial artery diameters were not different between
nonsmokers (4.2  0.02 mm), light smokers (4.3 
0.03 mm) and heavy smokers (4.4  0.01 mm) (ANOVA:
p  0.6). Flow-mediated EDV of the brachial artery was
not significantly different between light smokers and heavy
smokers (1.0  1.0% and 0.1  0.1%, p  0.52), but both
were significantly reduced compared with nonsmokers
(6.0  1.4%; ANOVA: p  0.001 for the groups; Post-hoc
Fisher PLSD: p  0.003 for nonsmokers vs. light smokers,
p  0.001 for nonsmokers vs. heavy smokers). By contrast,
the nitroglycerin-mediated (endothelium-independent) va-
sodilatory response of the brachial artery was not different
between all the groups (19.1  1.4% for nonsmokers,
22.4  3.6% for light smokers and 15.7  3.6% for heavy
smokers, ANOVA: p  0.34).
Effect of smoking on NO and ET-1 production. Human
umbilical endothelial cells exposed to light smokers’ and
heavy smokers’ serum in vitro showed a similar basal NO
production (Fig. 1A; 1,418  421 vs. 1,137  267 nM,
respectively, p  0.62). However, compared with the
nonsmokers’ group, both were significantly lower (3,613 
459 nM; ANOVA: p  0.0004 for the groups; post-hoc
Fisher PLSD: p  0.001 for nonsmokers vs. light smokers,
p  0.0003 for nonsmokers vs. heavy smokers).
Substance P-stimulated NO production was similar be-
tween the light smoker and heavy smoker group ( from
baseline: 145  87 vs. 121  120 nM, respectively, p 
0.95), but, compared with the nonsmoker group, both were
significantly lower ( from baseline: 1,057  455 nM;
ANOVA: p  0.05 for the groups; post-hoc Fisher PLSD:
p  0.04 for nonsmokers vs. light smokers, p  0.03 for
nonsmokers vs. heavy smokers).
Basal ET-1 production by the HUVECs treated with
nonsmokers’, light smokers’ and heavy smokers’ serum were
not different between the three groups (Fig. 1B; 283 
43 pg/ml, 326  24 pg/ml and 282  17 pg/ml, respec-
tively, ANOVA: p  0.55).
Effects of light and heavy smokers’ serum on eNOS
protein expression and eNOS activity in vitro. Human
umbilical endothelial cells treated with light smokers’ and
Table 1. Parameters of Smoke Exposure and Endothelial
Function of the Study Population
Nonsmokers
(n  8)
Light
Smokers
(n  7)
Heavy
Smokers
(n  8)
Cigarettes/day — 1.8  0.6 21  1*
Pack-years — 0.7  0.2 13  3*
Cotinine (ng/ml) 8  3 140  54† 286  26‡§
Baseline diameter (mm) 4.2  0.02 4.3  0.03 4.4  0.01
EDV (%) 6.0  1.4 1.0  1.0 0.1  0.1¶
Nitroglycerin-mediated
dilation (%)
19.1  1.4 22.4  3.6 15.7  3.6
Values are expressed as mean  SEM. *p  0.004 for light smokers versus heavy
smokers. Post-hoc Fisher protected least significant difference (PLSD): for serum
cotinine levels: †p  0.02 for nonsmokers versus light smokers; ‡p  0.0001 for
nonsmokers versus heavy smokers; §p  0.006 for light smokers versus heavy
smokers. Post-hoc Fisher PLSD: for endothelial-dependent vasodilation (EDV) (%):
p  0.003 for nonsmokers versus light smokers; ¶p  0.001 for nonsmokers versus
heavy smokers.
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Figure 2. Effects of light and heavy smokers’ serum on endothelial nitric
oxide synthase (eNOS) protein expression and eNOS activity in vitro.
Confluent (approximately 85%) human umbilical endothelial cells
(HUVECs) were incubated with an equal volume of medium and serum
from nonsmokers (n  8), light smokers (n  7) or heavy smokers (n  8)
in 24-well plates. After 12 h culture, supernatant was collected, and the
HUVECs were lysed. (A) Endothelial nitric oxide synthase protein
concentration of the cell lysates was determined by ELISA; (B) eNOS
activity of the cell lysates was determined by detecting the conversion of
[3H]L-arginine to [3H]L-citrulline. (A) Endothelial nitric oxide synthase
protein expression; one-way analysis of variance (ANOVA): group, p 
0.0001. Post-hoc Fishers protected least significant difference (PLSD):
*nonsmokers versus light smokers, p  0.0003; †nonsmokers versus heavy
smokers, p  0.0001; light smokers versus heavy smokers, p  0.40. (B)
Endothelial nitric oxide synthase activity; one-way ANOVA: group, p 
0.02. Post-hoc Fisher PLSD: *nonsmokers versus light smokers, p  0.03;
†nonsmokers versus heavy smokers, p  0.004; light smokers versus heavy
smokers, p 0.63. The box represents the interquartile range (between the
25th and 75th percentiles); the median is shown as a horizontal bar within
each box. The bars outside each box show the range of 95% of all values.
Figure 1. Effects of light and heavy smokers’ serum on basal-nitric oxide
(NO) and endothelin-1 (ET-1) production in vitro. Confluent (approxi-
mately 85%) human umbilical endothelial cells were incubated with an
equal volume of medium and serum from nonsmokers (n  8), light
smokers (n  7) or heavy smokers (n  8) in 24-well plates. After 12-h
incubation (37°C; 5% CO2), the cell culture supernatant was collected. (A)
Nitric oxide production in the cell culture supernatant was determined by
a chemiluminescence method; (B) Endothelin-1 production in the cell
culture supernatant was determined using an ELISA. (A) Basal NO
production; one-way analysis of variance (ANOVA): group, p  0.001.
Post-hoc Fishers protected least significant difference (PLSD): *nonsmok-
ers versus light smokers, p  0.001; †nonsmokers versus heavy smokers,
p  0.001; light smokers versus heavy smokers, p  0.62. (B) Basal ET-1
production; one-way ANOVA: group, p  0.55. The box represent the
interquartile range (between the 25th and 75th percentiles); the median is
shown as a horizontal bar within each box. The bars outside each box
show the range of 95% of all values.
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heavy smokers’ serum had similar eNOS protein expression
(Fig. 2A; 888  96 vs. 974  50 pg/ml, respectively, p 
0.40). However, both smokers’ groups showed significantly
higher eNOS protein expression as compared with the
nonsmokers (Fig. 2, A; 440  58 pg/ml; ANOVA: p 
0.0001 for the groups; post-hoc Fisher PLSD: p  0.0003
for nonsmokers vs. light smokers, p 0.0001 for nonsmok-
ers vs. heavy smokers).
The cell lysates utilized above were used to determine
eNOS activity, and specific eNOS activity for each sample
was adjusted for the amount of eNOS protein as detected by
ELISA. The cell lysates from HUVECs treated with either
light smokers’ or heavy smokers’ serum showed similar
eNOS activity (Fig. 2B; 1.25  0.21 vs. 1.11  0.16 pmol
L-citrulline/min/pg eNOS, respectively, p  0.63). How-
ever, both of these groups showed significantly lower eNOS
activity as compared with the nonsmokers (Fig. 2, B; 1.92
0.20 pmol L-citrulline/min/pg eNOS; ANOVA: p  0.02
for the groups; post-hoc Fisher PLSD: p  0.03 for
nonsmokers vs. light smokers, p 0.006 for nonsmokers vs.
heavy smokers).
Relationship between degree of smoke exposure, EDV
and NO production. Pack-years of smoke exposure repre-
sent long-term exposure, while serum cotinine represents
short-term smoke exposure (two to four days). On linear
regression analysis, no significant correlation was found
between EDV and pack-years (r 0.14, p 0.62) or serum
cotinine levels (r  0.20, p  0.55) in the smokers’ groups.
Similarly, no relationship could be found between in vitro
NO production and serum cotinine levels (r  0.30, p 
0.33) in the smokers’ groups. These results suggest that
dose-related detrimental effect of smoking on EDV and
NO production in both short- and long-term may not be
linear.
DISCUSSION
Impairment of EDV is one of the early steps that link
cardiovascular risk factors and clinical events (17,18). Using
a combined in vivo and in vitro model, we have previously
demonstrated that smoking is associated with reduced
EDV, which, in part, is a reflection of decreased production
or bioavailability of endothelial NO (16). In this study, even
a relatively small amount of active cigarette smoking ap-
peared capable of overwhelming the biochemical and cellu-
lar process of endothelial NO biosynthesis in vivo and in
vitro.
Degree of smoking, EDV and the NO biosynthetic
pathway. Celermajer et al. (8) found a dose-dependent
reduction of EDV in relation to pack-years of active smoke
exposure. On the contrary, in our study both the active
heavy and light smokers had a similar reduction in brachial
artery EDV compared with nonsmokers. It should be noted
that, in the present study, smokers were stratified into two
groups by the number of cigarettes smoked as opposed to
pack-years of smoking. Nevertheless, number of cigarettes
smoked per day, pack-years of smoke exposure and serum
cotinine levels were significantly lower in light smokers as
compared with heavy smokers. Interestingly, in a later
study, Celermajer et al. (13) reported that active and passive
smoke exposure caused a similar degree of dysfunction in
EDV of the brachial artery in the presence of significantly
different salivary cotinine levels. Likewise, Sumida et al.
(14), in addition to finding a similar reduction in vasodila-
tory function of the coronary arteries between active and
passive smokers, also found a similar reduction in coronary
artery vasodilatory function in individuals with heavy- and
light-passive smoke exposure. More recently, Woo et al.
(15) failed to a find a dose-dependent relation between the
duration of passive smoke exposure and reduced EDV of the
brachial artery. The above studies are consistent with our
own in vivo findings and parallel our in vitro observations
showing similar alterations in basal- and SP-stimulated NO
production, eNOS protein expression and activity in both
heavy and light smokers. These data suggest that active light
smoking can induce equivalent detrimental biochemical
changes leading to abnormal endothelial vasodilatory func-
tion as active heavy smoking.
ET-1 and smoking. Enothelin-1 is the most potent en-
dogenous vasoconstrictor produced by both the ECs and
vascular smooth-muscle cells (19). Available data on the
effects of cigarette smoke or its components on ET-1 levels
in the circulation or in various tissues are limited. Two early
studies suggested that within the first 10 min of active
smoking there is a rise in plasma or serum ET-1 level, which
is followed by a decline over time (20,21). More recently, in
a rat model, acute cigarette exposure was shown to increase
the expression of ET-1 messenger ribonucleic acid (mRNA)
in heart and lung tissues, but, with chronic cigarette
exposure, the effect on the ET-1 mRNA in cardiovascular
tissues became insignificant (22). Similarly, Barbera et al.
(23) found both ET-1 expression in pulmonary arteries and
endothelin content in lung tissue extracts were similar
between smokers and nonsmokers. These data, taken to-
gether with our in vitro finding of no difference in basal
ET-1 production among the three groups, suggest that the
increase in ET-1 production in response to active smoking
in the healthy individuals is probably a transient phenom-
enon and restricted only to the acute phase of smoking.
Implications of this study. Endothelial function encom-
passes the regulation of vasomotor tone, inflammation in
the vessel wall and the balance of the thrombotic/
thrombolytic factors at the lumen-wall interface (17,18).
Nitric oxide, the potent vasodilator secreted by ECs, plays a
pivotal role in regulation of all the components of endothe-
lial function (17,18). Endothelin-1, the potent vasoconstric-
tor also secreted by ECs, opposes the effects of NO (18,19).
Thus, a deficiency in NO or an increase in ET-1 can create
an unfavorable atmosphere in the lumen-wall interface
contributing to cardiovascular pathology. This study inves-
tigated the dose-related effect of active smoking on these
two molecules. Our data on NO and EDV in active smokers
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are consistent with the findings of other studies of active and
passive smoke exposure and show that the dose-response
curve for cardiovascular effects associated with tobacco
smoke exposure may not be linear (5–7,14,24,25). Further-
more, data from the model utilized in the present study
suggest that smoking appears to affect only the endothelial
NO biosynthesis without significantly altering EC- specific
ET-1 biosynthesis.
Study limitations. In the present study, several potential
limitations are recognized. First, while similar in vivo and in
vitro results in our study population substantiated our
findings, the number of subjects enrolled in our study group
was relatively small. Additional studies in a larger popula-
tion may be required to exclude a smaller than hypothesized
difference in biophysiology of EDV between light and heavy
smokers. Second, in the present study only EC-specific
ET-1 production was measured, but vascular-smooth mus-
cle cells (19) also contribute to circulatory ET-1. Thus, our
data should only be interpreted as an EC-specific response
to smoking. Third, the cardiovascular effects of smoking
leading to a clinical event depend on complex interactions
involving alterations in the biology of the vessel wall,
prothrombotic and proinflammatory molecules and cannot
be explained solely by the results of this study.
Conclusions. This study indicates that both heavy and
light active smoking (substantiated by pack years and serum
cotinine) can cause a similar degree of endothelial vasoregu-
latory dysfunction in vivo and similar alterations in NO
production, eNOS protein and its activity in vitro. Thus,
even a small amount of active smoke exposure appears to
have a significant effect on one of the early pathophysiologic
indicators for atherosclerosis and supports other data that
smoking even a small number of cigarettes has potentially
deleterious effects contributing to cardiovascular risk. Fur-
thermore, our study suggests that even a small amount of
smoke exposure may initiate yet-to-be-defined cellular
mechanisms that might overwhelm the biochemical process
of NO biosynthesis. Additional investigations are required
to elucidate such molecular and cellular mechanisms of
endothelial dysfunction.
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